Janssen submits Genmab-developed drug for EMA approval

Shortly after applying for US marketing approval for drug candidate teclistamab, which is based on Genmab’s duobody platform, the US-based pharmaceutical firm has followed this up with a European application with the EMA.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

The European Medicines Council (EMA) has just received a new marketing authorization application for teclistamab, a treatment for relapsed or refractory multiple myeloma, which is a type of bone marrow cancer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading